Jean Lee, MD
Nephrology · Philadelphia, PANPI 1083602189
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Calliditas Therapeutics US Inc. at 32.5% of the total. That places this record below the midpoint for nephrology clinicians in PA, where the typical reported total is $612.
Across 17 payments — averaging $43.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$241
- Vifor Pharma, Inc.$203
- Aurinia Pharma U.S., Inc.$101
- Novo Nordisk$49
- GSK$42
- Apellis Pharmaceuticals, Inc.$25
- plus $80 from 4 others
Across 37 payments — averaging $1091.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$22K
- Astrazeneca UK Limited$6K
- Baxter Healthcare$5K
- CSL Behring$4K
- Boehringer Ingelheim International GmbH$3K
What the payments were for
- Food & beverage$740100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 5 | $241 |
| Vifor Pharma, Inc. | 2 | $203 |
| Aurinia Pharma U.S., Inc. | 1 | $101 |
| Novo Nordisk | 2 | $49 |
| GSK | 2 | $42 |
| Apellis Pharmaceuticals, Inc. | 1 | $25 |
| Cormedix Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Amgen | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$740 in reported general payments places this provider in the 50th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 32 | $30,822 |
| ProcritEpoetin Alfa | 29 | $14,701 |
| RetacritEpoetin Alfa-Epbx | 24 | $5,100 |
| Sevelamer Carbonate | 12 | $1,039 |
| Bumetanide | 12 | $500 |
| Chlorthalidone | 18 | $275 |
| Furosemide | 36 | $240 |
| Carvedilol | 13 | $88 |
| Amlodipine Besylate | 17 | $81 |
| Spironolactone | 23 | $65 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Philadelphia
- Rakesh GulatiPhiladelphia$657K
- Raymond TownsendPhiladelphia$357K
- Ellie KelepourisPhiladelphia$287K
- Abdallahsassine GearaPhiladelphia$225K
- Katalin SusztakPhiladelphia$192K
- Debbie Cohen SteinPhiladelphia$112K
- Laura DemberPhiladelphia$110K
- Jonathan HoganPhiladelphia$100K
- Michael YoslovPhiladelphia$79K
- Michael LevinPhiladelphia$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.